Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 253-264
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.253
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.253
Figure 1 Expression of Lnc524369/YWHAZ/RAF1 in vitro.
A: Expression of Lnc524369 in human cancer cell lines (HepG2 and Huh 7) and normal liver cells (L02); B: Expression of Lnc524369 in the cytoplasm and nucleus of Huh 7 cells; C: Knock-in of Lnc524369 in Huh 7 cells; D: Western blot bands of YWHAZ and RAF1 protein; E: YWHAZ expression was increased by overexpression of Lnc524369; F: RAF1 expression was increased by overexpression of Lnc524369; G: YWHAZ protein was expressed in liver cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) database; H: RAF1 protein was expressed in liver cancer cell lines from the CCLE database.
- Citation: Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol 2022; 14(1): 253-264
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/253.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.253